Intervention Protocol

Duration of therapy for tuberculosis in patients infected with Human Immunodeficiency Virus

  1. Madhukar Pai1,*,
  2. Arthur L Reingold2,
  3. Lee W Riley3,
  4. John M Colford4,
  5. Olakunle Ojubolamo5,
  6. Thuli Mthiyane6

Editorial Group: Cochrane HIV/AIDS Group

Published Online: 22 JUL 2002

DOI: 10.1002/14651858.CD003821


How to Cite

Pai M, Reingold AL, Riley LW, Colford JM, Ojubolamo O, Mthiyane T. Duration of therapy for tuberculosis in patients infected with Human Immunodeficiency Virus (Protocol). Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD003821. DOI: 10.1002/14651858.CD003821.

Author Information

  1. 1

    McGill University, Assistant Director for Global Health Research, MUHC-Research Institute, Montreal , QC, Canada

  2. 2

    University of California at Berkeley, Division of Epidemiology, Berkeley, CA, USA

  3. 3

    University of California at Berkeley, Division of Infectious Diseases, Berkeley, CA, USA

  4. 4

    University of California at Berkeley, Epidemiology, Berkeley, CA, USA

  5. 5

    Glasgow, UK

  6. 6

    Medical Research Council, Durban, South Africa

*Madhukar Pai, Assistant Director for Global Health Research, MUHC-Research Institute, McGill University, Purvis Hall, Room 50, 1020 Pine Avenue West, Montreal , QC, H3A 1A2, Canada. madhukar.pai@mcgill.ca .

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 22 JUL 2002

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The aim of our systematic review is to assess the effects of an extended duration of the standard short course anti-tuberculosis chemotherapy (more than 6 months) on recurrence, cure, mortality, treatment failure, and adverse events in HIV-infected patients, using all available randomized controlled trials.